0 396

Cited 19 times in

Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review

 Sang Hui Chu  ;  Young Joo Lee  ;  Eon Sook Lee  ;  Yimin Geng  ;  Xin Shelley Wang  ;  Charles S. Cleeland 
 SUPPORTIVE CARE IN CANCER, Vol.23(2) : 513-524, 2015 
Journal Title
Issue Date
Amitriptyline/therapeutic use ; Anticonvulsants/therapeutic use* ; Antidepressive Agents/therapeutic use* ; Antineoplastic Agents/adverse effects* ; Antineoplastic Agents/therapeutic use ; Boronic Acids/adverse effects ; Boronic Acids/therapeutic use ; Bortezomib ; Carbamazepine/analogs & derivatives ; Carbamazepine/therapeutic use ; Central Nervous System/drug effects* ; Cyclohexanols/therapeutic use ; Duloxetine Hydrochloride ; Epothilones/adverse effects ; Epothilones/therapeutic use ; Humans ; Neoplasms/drug therapy* ; Neuralgia/drug therapy ; Peripheral Nervous System Diseases/chemically induced ; Peripheral Nervous System Diseases/drug therapy* ; Pyrazines/adverse effects ; Pyrazines/therapeutic use ; Taxoids/adverse effects ; Taxoids/therapeutic use ; Thalidomide/adverse effects ; Thalidomide/therapeutic use ; Thiophenes/therapeutic use ; Venlafaxine Hydrochloride ; Vinca Alkaloids/adverse effects ; Vinca Alkaloids/therapeutic use
Anticonvulsants ; Antidepressants ; Cancer ; Chemotherapy ; Peripheral neuropathy
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is common among cancer patients who undergo chemotherapy with platinum analogues, taxanes, vinca alkaloids, epothilone, bortezomib, and thalidomide. The purpose of this study was to investigate the evidence of using drugs affecting the central nervous system (CNS) to alleviate CIPN in cancer patients. METHODS: A systematic literature search was conducted using the CINAHL, EMBASE, and Medline databases to identify randomized controlled clinical trials (RCTs) reported in English up to 2013. We identified ten trials of CNS-acting drugs used to treat CIPN in cancer patients and reviewed efficacy and safety of CNS-acting drugs for CIPN using a standard data collection form. The risk of bias in each RCT was also assessed. RESULTS: Antidepressants were used in six studies and anticonvulsants in four studies. We found positive results for amitriptyline (topical), venlafaxine, and oxcarbazepine in one study each, but the results were not sufficient to draw definite conclusions. One trial with duloxetine showed a moderate effect (effect size, 0.513, P = .003) on CIPN pain relief. However, none of the results has yet been duplicated in an RCT with a large sample size. CONCLUSIONS: Insufficient RCTs exist to confirm the efficacy of CNS agents to reduce CIPN. This study highlighted the need for and the importance of conducting well-designed RCTs to generate evidence on CIPN symptom management. Additional RCTs are warranted to accelerate the potential use of CNS drugs for CIPN in cancer patients.
Full Text
Appears in Collections:
3. College of Nursing (간호대학) > Dept. of Nursing (간호학과) > 1. Journal Papers
Yonsei Authors
Chu, Sang Hui(추상희) ORCID logo https://orcid.org/0000-0001-6877-5599
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.